Who Paid My Doc
Mark Jacobs
Advanced Heart Failure and Transplant Cardiology New Haven, CT Medical Doctor
NPI 1821445735 CMS profile 4224802
20 York St, Baird Hall 20Th Flr, New Haven, CT 06510
General payments
$1,741
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Mark Jacobs of New Haven, CT is reported in the CMS Open Payments database as having received $1,741 across 36 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 22nd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $543 | 7 | |
| 2023 | General | $774 | 10 | |
| 2022 | General | $131 | 7 | |
| 2021 | General | $220 | 7 | |
| 2020 | General | $73 | 5 |
Beside peers
- Mark Jacobs
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Mark Jacobs were reported at $0. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Mark Jacobs | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $863 | $224–$4,562 | $163 |
| 2020 | $73 | $452 | $122–$3,992 | $114 |
| 2021 | $220 | $550 | $159–$3,571 | $132 |
| 2022 | $131 | $729 | $221–$4,357 | $149 |
| 2023 | $774 | $1,002 | $309–$5,827 | $160 |
| 2024 | $543 | $931 | $273–$5,204 | $164 |
| 2025 | $0 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
13
Drug cost
$8,756
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 13 | $8,756 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
36 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Advanced Heart Failure and Transplant Cardiology in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.